ArticleDiscover oncology2025
Mendelian randomization analysis of immune cell traits and their association with cervical cancer risk.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is one of the most common malignancies among women worldwide, with a complex pathogenesis involving multiple genetic and immune factors. Immune cells play a critical role in the initiation and progression of tumors. This study aimed to investigate the causal relationship between various immune cell traits and cervical cancer risk using Mendelian randomization (MR), with the goal of providing new insights and potential targets for the prevention and treatment of cervical cancer.
methodsThis study employed Mendelian randomization analysis, using genetic variants as instrumental variables to evaluate the association between various immune cell traits and cervical cancer risk. By analyzing the effect sizes and statistical significance of different immune cell subsets, and utilizing visual tools such as volcano plots, forest plots, and funnel plots, a comprehensive analysis of the data was conducted.
resultsThe study found a slight positive association between activated secretory CD4 regulatory T cells and cervical cancer risk (OR = 1.001, 95% CI 1.000-1.002, p = 0.001), while resting CD4 regulatory T cells showed a potential protective effect (OR = 0.998, 95% CI 0.997-0.999, p = 0.004). Additionally, CD25 on IgD+ CD38dim B cells approached significance (p = 0.050), suggesting a possible impact. Most other immune cell traits had effect sizes close to zero and showed no significant association with cervical cancer risk.
conclusionAlthough most immune cell traits showed no significant association with cervical cancer risk, these significant findings provide direction for future research and highlight the potential role of specific immune cells in the pathogenesis of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.